| 1 | ClinicalTrials.gov (NCT00090532) A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration. U.S. National Institutes of Health. | 
                        
                | 2 | Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933. | 
                        
                | 3 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | 
                        
                | 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | 
                        
                | 5 | Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53. | 
                        
                | 6 | Clinical pipeline report, company report or official report of Amgen | 
                        
                | 7 | National Cancer Institute Drug Dictionary (drug id 452042). | 
                        
                | 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | 
                        
                | 9 | Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114. | 
                        
                | 10 | CA patent application no. 841416, Method of selecting therapeutic indications. | 
            
            
                |  |  |  |  |  |  |